Canaccord Genuity Reiterates Buy Rating for Mast Therapeutics, Inc. (NASDAQ:SVRA)

Canaccord Genuity reaffirmed their buy rating on shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) in a report released on Monday, July 17th. They currently have a $18.00 target price on the stock.

Shares of Mast Therapeutics (NASDAQ SVRA) traded down 1.90% on Monday, hitting $5.67. 22,172 shares of the stock were exchanged. The stock’s market cap is $78.29 million. The company’s 50 day moving average is $6.26 and its 200-day moving average is $5.96. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $9.88.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/11/mast-therapeutics-inc-nasdaqsvra-rating-reiterated-by-canaccord-genuity-updated-updated-updated.html.

In related news, insider Jaakko Taneli Jouhikainen acquired 10,500 shares of the business’s stock in a transaction on Wednesday, June 7th. The shares were bought at an average price of $4.75 per share, with a total value of $49,875.00. Following the completion of the acquisition, the insider now owns 235,326 shares in the company, valued at $1,117,798.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Joseph S. Mccracken acquired 52,250 shares of the business’s stock in a transaction on Wednesday, June 7th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $248,187.50. Following the acquisition, the director now owns 59,866 shares of the company’s stock, valued at approximately $284,363.50. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 64,850 shares of company stock worth $308,038. 4.26% of the stock is owned by corporate insiders.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

What are top analysts saying about Mast Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mast Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit